{
  "docId": "019de076-0bfb-77a4-9766-824e83d61c36",
  "docSlug": "78f42e9d8d70fea2dc2370a17955f7e7",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 52,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Slide 26 of a pitch deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/26",
  "deckHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36",
  "deckJsonHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json",
  "deckAnchorHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.076,
        "y": 0.885
      },
      "kind": "disclaimer",
      "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; RP2D, recommended phase 2 dose. Source: Adapted from Drilon A. et al., EORTC-NCI-AACR 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4d0c666-3f0a-47d5-93f4-e19beb2fc446",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.85,
        "x": 0.076,
        "y": 0.58
      },
      "kind": "list",
      "text": "This preliminary dataset indicates encouraging clinical activity in a heavily pre-treated population, with responses observed in patients: with and without ROS1 G2032R resistance; who progressed through lorlatinib or repotrectinib; with brain metastases.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b026920-18c0-4c07-a0bb-507aef281dd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.85,
        "x": 0.076,
        "y": 0.305
      },
      "kind": "list",
      "text": "In the ongoing ARROS-1 Phase 1 dose-escalation, a wide dose range resulted in exposures exceeding predicted efficacy thresholds without indication of off-target toxicity. NVL-520 has been well tolerated with no DLTs. No dose reductions or treatment discontinuations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "637f6b40-768b-4be3-9414-83ca408d1c04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.85,
        "x": 0.076,
        "y": 0.145
      },
      "kind": "title",
      "text": "NVL-520 is a brain-penetrant, selective inhibitor of ROS1 and ROS1 resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5d1dbec-41f4-4720-9205-041bd99bafb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.576,
        "x": 0.076,
        "y": 0.105
      },
      "kind": "title",
      "text": "OCTOBER 2022 CONCLUSIONS – PRELIMINARY DOSE ESCALATION DATA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c475683-cfe2-4ddb-a9f2-80807e2a815f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 45,
      "from": 13,
      "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}